Genzyme/Isis’ Mipomersen Development Outlook Pricier And Riskier After FDA Weighs In
This article was originally published in The Pink Sheet Daily
Executive Summary
Cardiotoxicity and outcomes requirements push back NDA timeline for the novel LDL-lowering drug.